Health services M&A is active in 2026, but uncertainty slows volume: PwC

Bypaulgruensfelder
Healthcare Dive June 22, 2026
Read Full Article →
AI-Generated Summary

Healthcare M&A deal value surged in early 2026 — $18 billion in Q1 and $11 billion through May in Q2 — far outpacing H1 2025 totals, according to a new PwC analysis. But deal volume has softened as buyers grow more selective amid reimbursement uncertainty and Medicaid funding pressure from the “Big Beautiful Bill.” PwC finds investors are prioritizing assets with strong margin profiles, scalable operations, and proven financial returns. AI tools remain attractive to dealmakers but must demonstrate hard-dollar ROI: “Pilot-stage claims no longer justify valuation uplift.” Revenue cycle management and clinical documentation AI are showing the strongest returns.

Why It Matters

Deal value nearly doubling while volume falls means fewer, bigger, more selective checks. Operators preparing for a sale should expect deeper diligence on reimbursement stability and margin durability — and AI capabilities only add value when they show hard-dollar returns.

healthcare M&A PwC deal outlook PE selectivity reimbursement uncertainty deal valuation RCM AI

While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.

Frequently asked questions

How much healthcare M&A value closed in early 2026?

About $18 billion in Q1 and another $11 billion in Q2 through the end of May, per PwC — well ahead of comparable H1 2025 totals — even as deal count softened with buyers growing more selective.

What are buyers prioritizing in 2026 health services deals?

Assets with proven reimbursement stability, strong margin profiles, and scalable operations. Policy uncertainty and Medicaid funding pressure from the “Big Beautiful Bill” have raised the bar for what gets funded.

Does AI raise a healthcare company’s valuation in 2026?

Only when it demonstrates hard-dollar financial returns — PwC notes pilot-stage claims no longer justify valuation uplift. Revenue cycle management and clinical documentation AI are showing the strongest returns.

Similar Posts

  • Dentalcorp Enters U.S. Market With Northstar Dental Acquisition

    Bypaulgruensfelder

    Dentalcorp, one of North America’s largest dental support organizations, has entered the U.S. market by acquiring Northstar Dental Partners, a Boca Raton-based group supporting 21 practices across Florida. The deal, with terms undisclosed, expands Dentalcorp’s network to more than 650 supported practices and roughly six million annual patient visits, and marks the Canadian DSO’s first move south of the border. Founder Dr. Jordan Tomalty retains an ownership stake and a leadership role. For Dentalcorp, Florida provides a foothold in one of the fastest-growing U.S. healthcare markets and a platform for further acquisitions in a still-fragmented dental landscape.

  • How RCM Performance Drives ASC Valuation Multiples in 2026

    Bypaulgruensfelder

    Ambulatory surgery centers preparing to sell in 2026 are seeing buyers price deals on revenue cycle performance as much as case volume, according to VMG Health. Historical ASC sale multiples have run 7-8x EBITDA, with best-in-class centers commanding double-digit multiples, but VMG Health’s deal team says buyers now apply heavier diligence to collections discipline, payer mix, and denial management before underwriting that premium. The firm, drawing on transactions led by Christa Shephard, Chad Zoretic, Debra Stinchcomb, and Nancy Stephens, also flags leadership and management infrastructure and physician alignment as valuation drivers distinct from financial metrics, since centers dependent on one or two physicians or lacking a transferable management layer carry higher post-close execution risk that buyers price into their offers.

  • 73% of Healthcare Sites Run Ad Trackers That Ignore Opt-Outs

    Bypaulgruensfelder

    73% of 59 major U.S. hospital and clinic websites were running advertising or marketing trackers even when visitors sent an active Global Privacy Control opt-out signal, according to an independent audit conducted by Verified Data for Piwik PRO. Sixty-nine percent used marketing or advertising cookies, and the narrow gap between the two figures indicates some trackers operate without cookies — meaning cookie-blocking alone does not close the exposure. Scans detected 75 unique tracking tools across the sites, including Google Marketing Platform on 33 domains and Google Analytics on 20. Cumulative healthcare pixel enforcement actions and settlements have exceeded $100 million since 2023.

  • Optimizely Enters the AEO Race With Agent Visibility Analytics

    Bypaulgruensfelder

    Optimizely launched a full Answer Engine Optimization (AEO) platform on June 10, 2026, introducing Agent Visibility Analytics and a new data-sharing partnership with Conductor. Built inside Optimizely Analytics, the tool uses log-level data, not modeled estimates, to show which AI agents and crawlers are accessing a site’s content, classified by intent and broken out by funnel stage or topic area. The launch pairs that visibility layer with two autonomous agents: one that flags content gaps versus competitors in AI search results, and one that benchmarks AI-driven share of voice. The release follows similar AEO moves from Siteimprove, HubSpot, Webflow, and Sitecore, as Google’s AI Mode surpasses 1 billion monthly active users.

  • CMS Proposes 2027 Physician Payment Overhaul: MIPS Sunset and ACO Expansion

    Bypaulgruensfelder

    CMS’s proposed CY 2027 Physician Fee Schedule rule would sunset traditional MIPS reporting in 2029, replace it with specialty-focused MIPS Value Pathways covering roughly 98% of specialties, and make Medicare ACOs easier to join and more rewarding. The Medicare Shared Savings Program — which paid $4.1 billion in shared savings to 75% of its 476 ACOs for 2024 while generating about $2.5 billion in net Medicare savings — would gain new-entrant financial incentives, more predictable spending benchmarks, and the option to reduce beneficiary cost-sharing starting April 2027. CMS also proposes recalibrating physician payment rates, introducing MIPS Core Measures in 2027, and closing an APM incentive loophole worth an estimated $2.38 billion over a decade.

  • The Attribution Problem Your Board Doesn’t Understand

    Bypaulgruensfelder

    Healthcare marketing attribution is genuinely hard for multi-site groups because patient journeys are long, largely offline, and privacy-constrained—and a budget you can’t defend is a budget that gets cut. Strategy Collective’s Matt Lee argues perfect attribution doesn’t exist, but ‘good enough’ attribution is achievable through four moves: call tracking, redesigned patient intake questions, a blended market-level report, and separating brand demand from generated demand. The bigger fix is reframing the board conversation itself. Instead of asking ‘is marketing working?’, leaders should ask ‘how do we make Market B look like Market A?’—shifting from an unwinnable ROI-proof debate to a comparative, market-level view that drives real reallocation decisions.